Myriad Genetics presents two new studies at American Urological Association.
Myriad Genetics announced new data from two studies presented at the Western Section of the American Urological Association annual meeting. The key results are that the Prolaris test is superior to adverse pathology at predicting the risk of prostate cancer biochemical recurrence after surgery, and the myRisk Hereditary Cancer test found one in ten men with prostate cancer carry an inherited genetic mutation in a cancer-causing gene. The first study compared the Prolaris test to radical prostatectomy, or RP, derived adverse pathology in predicting biochemical recurrence after surgery. The analysis included 557 men with low-risk prostate cancer treated by RP. The Prolaris test score was also combined with prostate risk assessment score to generate a clinical cell-cycle risk score. The findings show that the Prolaris test with CAPRA was 2.5 times more predictive than adverse pathology in predicting biochemical recurrence after surgery. After accounting for CAPRA, the Prolaris test score was 2 times more predictive than adverse pathology, confirming that Prolaris provided more prognostic information than AP for predicting surgical failure. The second study is one of the largest-ever studies to assess hereditary cancer genetic testing for men with prostate cancer. It included 2,609 men who met guidelines for testing and were tested with the myRisk Hereditary Cancer test from 2013 to 2018. Approximately 75% of men had prostate cancer only and 25% had prostate cancer plus one other type of cancer. The results demonstrate that 10% of men with prostate cancer were found to carry a pathogenic mutation, and the most common mutations were found in the BRCA1/2, ATM, CHEK2 and the MMR genes. In men who had prostate cancer plus another cancer, the likelihood of having a deleterious mutation increased by 60%. Importantly, many of the mutations identified in this study were in genes associated with Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome.
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 2, 2018|
|Previous Article:||Ally Financial providing Carvana with up to $2.3B in financing.|
|Next Article:||Ally Financial providing Carvana with up to $2.3B in financing.|